EUVIMEDEUVIMED entdecken
Crossref

Neoadjuvant Atezolizumab in Patients With Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma

Vasu Divi, Sumaira Aasi, Saad A. Khan, Lily Lam, Luis Martinez Ramirez, John B. Sunwoo, Mobeen Rahman, Yifei Ma, Monika Kurzymski, Fred M. Baik, Michelle Chen, Andrey Finegersh und 7 weitere

JCO Oncology Advances · 2024-11 · (1)

DOI: 10.1200/oa-24-00058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Advances, 2024-11. Verfasst von Vasu Divi und 18 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To evaluate the feasibility of administering three doses of neoadjuvant atezolizumab before curative surgical resection in patients with advanced cutaneous squamous cell carcinoma (cSCC). PATIENTS AND METHODS This single-arm phase II trial included patients with cSCC of the head and neck with stage III or IV disease, or stage II lesions for which standard therapy would incur an unacceptable morbidity. Patients received up to three doses of atezolizumab at a fixed dose of 1,200 mg every 21 days before undergoing surgical resection. The primary end point was the percentage of patients able to complete three doses of therapy and be eligible for surgical resection without discontinuation due to toxicity or progression. Secondary end points included unconfirmed RECIST 1.1 response rate, pathological response rate (major and complete pathological response), and safety and tolerability of atezolizumab. RESULTS Twenty patients were enrolled and treated. Sixteen (80%) of 20 patients completed three doses of atezolizumab, and all patients were eligible for surgical resection. A pathological complete response was seen in seven (35%; 95% CI, 15.4 to 59.2) patients, and a major pathological response (

Zitieren

APA

Divi, V., Aasi, S., Khan, S. A., Lam, L., Ramirez, L. M., Sunwoo, J. B., Rahman, M., Ma, Y., Kurzymski, M., Baik, F. M., Chen, M., Finegersh, A., Hirotsu, K. E., Holsinger, F. C., Kibbi, N., Sirjani, D., Bedi, N., Pinto, H., & Colevas, A. D. (2024). Neoadjuvant Atezolizumab in Patients With Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma. JCO Oncology Advances. https://doi.org/10.1200/oa-24-00058

Vancouver

Divi V, Aasi S, Khan SA, Lam L, Ramirez LM, Sunwoo JB, et al. Neoadjuvant Atezolizumab in Patients With Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma. JCO Oncology Advances. 2024. doi:10.1200/oa-24-00058

BibTeX
@article{Divi2024,
  author = {Divi, Vasu and Aasi, Sumaira and Khan, Saad A. and Lam, Lily and Ramirez, Luis Martinez and Sunwoo, John B. and Rahman, Mobeen and Ma, Yifei and Kurzymski, Monika and Baik, Fred M. and Chen, Michelle and Finegersh, Andrey and Hirotsu, Kelsey E. and Holsinger, F. Chris and Kibbi, Nour and Sirjani, Davud and Bedi, Nikita and Pinto, Harlan and Colevas, A. Dimitrios},
  title = {Neoadjuvant Atezolizumab in Patients With Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma},
  journal = {JCO Oncology Advances},
  year = {2024},
  number = {1},
  doi = {10.1200/oa-24-00058}
}
Kostenlos starten →